MA46981A - Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine - Google Patents

Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine

Info

Publication number
MA46981A
MA46981A MA046981A MA46981A MA46981A MA 46981 A MA46981 A MA 46981A MA 046981 A MA046981 A MA 046981A MA 46981 A MA46981 A MA 46981A MA 46981 A MA46981 A MA 46981A
Authority
MA
Morocco
Prior art keywords
benzimidazole derivatives
bromodomain inhibitors
bromodomain
inhibitors
benzimidazole
Prior art date
Application number
MA046981A
Other languages
English (en)
Inventor
Rino Antonio Bit
John Alexander Brown
Philip G Humphreys
Katherine Louise Jones
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA46981A publication Critical patent/MA46981A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
MA046981A 2015-03-19 2016-03-17 Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine MA46981A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1504689.9A GB201504689D0 (en) 2015-03-19 2015-03-19 Chemical compounds

Publications (1)

Publication Number Publication Date
MA46981A true MA46981A (fr) 2019-10-09

Family

ID=53052091

Family Applications (2)

Application Number Title Priority Date Filing Date
MA046981A MA46981A (fr) 2015-03-19 2016-03-17 Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA041778A MA41778A (fr) 2015-03-19 2016-03-17 Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA041778A MA41778A (fr) 2015-03-19 2016-03-17 Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine

Country Status (36)

Country Link
US (2) US10442786B2 (fr)
EP (2) EP3271349B1 (fr)
JP (1) JP6419990B2 (fr)
KR (1) KR102072850B1 (fr)
CN (1) CN107635989B (fr)
AR (1) AR103934A1 (fr)
AU (1) AU2016232217B2 (fr)
BR (1) BR112017019779B1 (fr)
CA (1) CA2979504C (fr)
CL (1) CL2017002332A1 (fr)
CO (1) CO2017009992A2 (fr)
CR (1) CR20170430A (fr)
CY (1) CY1121855T1 (fr)
DK (1) DK3271349T3 (fr)
DO (1) DOP2017000213A (fr)
EA (1) EA033594B1 (fr)
ES (1) ES2735417T3 (fr)
GB (1) GB201504689D0 (fr)
HR (1) HRP20191186T1 (fr)
HU (1) HUE044414T2 (fr)
IL (1) IL254318B (fr)
LT (1) LT3271349T (fr)
MA (2) MA46981A (fr)
ME (1) ME03485B (fr)
MX (1) MX2017012023A (fr)
PE (1) PE20180032A1 (fr)
PH (1) PH12017501620A1 (fr)
PL (1) PL3271349T3 (fr)
PT (1) PT3271349T (fr)
RS (1) RS59056B1 (fr)
SG (1) SG11201707356QA (fr)
SI (1) SI3271349T1 (fr)
SM (1) SMT201900428T1 (fr)
TW (1) TW201706257A (fr)
UY (1) UY36589A (fr)
WO (1) WO2016146738A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
JP2018527340A (ja) 2015-08-11 2018-09-20 ネオメド インスティテュートＮｅｏｍｅｄ Ｉｎｓｔｉｔｕｔｅ アリール置換ジヒドロキノリノン、その調製及び医薬品としてのその使用
CA2994478C (fr) 2015-08-12 2023-10-03 Neomed Institute Benzimidazoles substitues, preparation et utilisation de ceux-ci en tant qu'agents pharmaceutiques
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
WO2017127930A1 (fr) 2016-01-28 2017-08-03 Neomed Institute [1,2,4]triazolo[4,3-a]pyridines substituées, leur préparation et leur utilisation comme médicaments
GB201614934D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
GB201614940D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
GB201614939D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Ip Dev Ltd Crystalline hydrate
TW202332436A (zh) 2017-04-18 2023-08-16 美商塞爾基因定量細胞研究公司 治療用化合物
CN109280046B (zh) * 2017-07-21 2021-02-02 浙江海正药业股份有限公司 苯并咪唑类衍生物及其制备方法及其在医药上的用途
EP3750885A4 (fr) * 2018-02-06 2021-10-27 Shanghai Haihe Pharmaceutical Co., Ltd. Composé présentant une activité inhibitrice de bet, son procédé de préparation et son utilisation
CN109369432B (zh) * 2018-11-02 2021-06-25 永农生物科学有限公司 (s)-4-氯-2-氨基丁酸酯的制备方法
JP2022053557A (ja) * 2019-02-08 2022-04-06 マルホ株式会社 ピリドン誘導体
CN119684285A (zh) * 2019-03-15 2025-03-25 福马治疗股份有限公司 抑制环amp-应答元件结合蛋白(creb)
US12497395B2 (en) 2019-04-24 2025-12-16 Convergene, Llc Small molecule bromodomain inhibitors and uses therof
WO2020223370A1 (fr) * 2019-04-29 2020-11-05 The Board Of Regents Of The University Of Texas System Compositions et méthodes de traitement d'infections à schistosomes
CN116217416A (zh) * 2022-12-31 2023-06-06 黄淮学院 一种苯并咪唑类药物中间体3-硝基-4-乙基氨基苯甲醇的制备方法
AU2024279724A1 (en) * 2023-05-30 2025-12-11 16380026 Canada Inc. Cyp26b1 inhibitor compounds and methods of use thereof
CN119219631B (zh) * 2024-12-04 2025-04-18 山东大学 一种bet蛋白溴结构域bd1选择性共价抑制剂及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
CN101460483B (zh) 2006-03-31 2013-05-08 詹森药业有限公司 作为组胺h4受体调节剂的苯并咪唑-2-基嘧啶和吡嗪
WO2011056635A1 (fr) * 2009-10-27 2011-05-12 Glaxosmithkline Llc Benzimidazoles utilisés en tant qu'inhibiteurs de l'acide gras synthase
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP3170813B1 (fr) 2010-10-06 2018-12-12 GlaxoSmithKline LLC Dérivés de benzimidazole comme inhibiteurs de pi3 kinase
GB201114103D0 (en) * 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013097052A1 (fr) * 2011-12-30 2013-07-04 Abbott Laboratories Inhibiteurs de bromodomaine
WO2014096965A2 (fr) * 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Nouveaux composés hétérocycliques en tant qu'inhibiteurs de bromodomaine
JP6325078B2 (ja) 2013-03-15 2018-05-16 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． ヘテロ環式化合物およびその使用
TWI530499B (zh) 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
TWI527811B (zh) * 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
WO2015004533A2 (fr) * 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Nouveaux composés bicycliques substitués utilisés comme inhibiteurs de bromodomaines
US20150051208A1 (en) * 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
US9428515B2 (en) * 2014-05-09 2016-08-30 Boehringer Ingelheim International Gmbh Benzimidazole derivatives
GB201504694D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201614939D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Ip Dev Ltd Crystalline hydrate

Also Published As

Publication number Publication date
AU2016232217A1 (en) 2017-10-12
IL254318B (en) 2019-08-29
UY36589A (es) 2016-10-31
BR112017019779A2 (en) 2018-05-22
IL254318A0 (en) 2017-11-30
US10442786B2 (en) 2019-10-15
KR102072850B1 (ko) 2020-02-03
CN107635989B (zh) 2020-12-08
EP3271349B1 (fr) 2019-05-15
TW201706257A (zh) 2017-02-16
PE20180032A1 (es) 2018-01-09
US20180044317A1 (en) 2018-02-15
US11053212B2 (en) 2021-07-06
SI3271349T1 (sl) 2019-08-30
CR20170430A (es) 2017-11-08
SG11201707356QA (en) 2017-10-30
EA033594B1 (ru) 2019-11-07
MA41778A (fr) 2018-01-24
HRP20191186T1 (hr) 2019-10-04
CA2979504A1 (fr) 2016-09-22
CN107635989A (zh) 2018-01-26
AR103934A1 (es) 2017-06-14
BR112017019779B1 (pt) 2023-10-03
DK3271349T3 (da) 2019-08-05
JP6419990B2 (ja) 2018-11-07
HUE044414T2 (hu) 2019-10-28
EP3271349A1 (fr) 2018-01-24
DOP2017000213A (es) 2017-10-15
CY1121855T1 (el) 2020-07-31
RS59056B1 (sr) 2019-08-30
EA201791973A1 (ru) 2018-07-31
MX2017012023A (es) 2018-01-30
AU2016232217B2 (en) 2019-04-04
LT3271349T (lt) 2019-07-10
PT3271349T (pt) 2019-08-19
WO2016146738A1 (fr) 2016-09-22
PL3271349T3 (pl) 2019-10-31
CO2017009992A2 (es) 2018-01-05
ME03485B (fr) 2020-01-20
JP2018507903A (ja) 2018-03-22
EP3549939A1 (fr) 2019-10-09
GB201504689D0 (en) 2015-05-06
CL2017002332A1 (es) 2018-03-16
US20200039953A1 (en) 2020-02-06
CA2979504C (fr) 2023-10-10
ES2735417T3 (es) 2019-12-18
SMT201900428T1 (it) 2019-09-09
PH12017501620A1 (en) 2018-02-12
KR20170129871A (ko) 2017-11-27

Similar Documents

Publication Publication Date Title
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
EP3386981A4 (fr) Hétérocycles utiles en tant qu'agents anticancereux
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
HUE056634T2 (hu) Rákellenes szerekként hasznos szubsztituált karbonukleozid-származékok
MA40770A (fr) Dérivés d'imidazoles pentacyclic fusionnés
EP3277381C0 (fr) Dérivés de nitrobenzyle d'agents anticancéreux
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
ME03776B (fr) Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
EP3457851A4 (fr) Dérivés de sobétirome
SI4119569T1 (sl) Konjugirane protismiselne spojine za uporabo v terapiji
EP3541374A4 (fr) Dérivés d'indazole utiles en tant qu'inhibiteurs de la diacylglycéride o-acyltransférase 2
MA41542A (fr) Nouveaux dérivés de n-acyl-arylsulfonamide utilisés en tant qu'inhibiteurs d'aminoacyl-arnt synthétase